MEI Pharma
San Diego, US · Delaware corporation · 5 known investors
Lite Strategy, Inc. (NASDAQ: LITS) is a publicly traded treasury company that accumulates and manages Litecoin (LTC) holdings, aiming to increase LTC exposure per share for its shareholders. It positions itself as a way for public-market investors to gain exposure to Litecoin.
BiotechCrypto & Web3FintechHealthtech
Founders & leadership
DM
David M. UrsoExecutive
DP
Daniel P. GoldExecutive
BG
Brian G. DrazbaExecutive
MF
Mr. FileChief Executive Officer & Board Member (former CFO)
KE
Kevan E. ClemensNamed on SEC filing
TC
Thomas C. ReynoldsNamed on SEC filing
RD
Robert D. MassNamed on SEC filing
CV
Charles V. Baltic IIINamed on SEC filing
Board
FW
Frederick W. DriscollBoard director
CA
Christine A. WhiteBoard director
NR
Nicholas R. GloverBoard director
WD
William D. RueckertBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$75M disclosed across 1 round · 2018
▶$75MraisedMay 2018 · 20 investors · PharmaceuticalsRule 506(b)
▶$75MraisedMay 2018 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frederick W. DriscollDirector
- Christine A. WhiteDirector
- David M. UrsoExecutive Officer
- Nicholas R. GloverDirector
- William D. RueckertDirector
- Daniel P. GoldExecutive Officer, Director
- Kevan E. ClemensDirector
- Thomas C. ReynoldsDirector
- Robert D. MassExecutive Officer
- Brian G. DrazbaExecutive Officer
- Charles V. Baltic IIIDirector
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $4.5M
- Placement agents
- Laidlaw & Company (UK) Ltd., Suntrust Investment Services, Inc., Oppenheimer & Co. Inc., Wells Fargo Securities, LLC, Stifel, Nicolaus & Company, Incorporated, BTIG, LLC
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does MEI Pharma do?
- Lite Strategy, Inc. (NASDAQ: LITS) is a publicly traded treasury company that accumulates and manages Litecoin (LTC) holdings, aiming to increase LTC exposure per share for its shareholders. It positions itself as a way for public-market investors to gain exposure to Litecoin.
- Who are MEI Pharma's investors?
- MEI Pharma's investors include 3B Future Health Fund, Aisling Capital, GSR, New Enterprise Associates (NEA), Vivo Capital.
- How much funding has MEI Pharma raised?
- MEI Pharma has disclosed $75M raised across 1 round.
- Where is MEI Pharma headquartered?
- MEI Pharma is headquartered in San Diego, US.